POEMS Syndrome Clinical Trial
Official title:
An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome
The purpose of this prospective study is to determine the efficacy and safety of lenalidomide plus dexamethasone in patients with newly diagnosed POEMS syndrome.
The investigators propose to use the adverse effects as well as the need for dose reduction
as a criterion to judge tolerability of treatment.
The primary endpoint would be hematological response rate according to international myeloma
working group (IMWG) response criteria for amyloidosis and neurological response rate defined
by overall neuropathy limitation scale (ONLS) score.
This study expects to enroll approximately 41 subjects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06040567 -
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
|
||
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT04396496 -
Treatment of POEMS Syndrome With Daratumumab
|
Phase 2 | |
| Recruiting |
NCT05263817 -
A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis
|
Early Phase 1 | |
| Active, not recruiting |
NCT02921893 -
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
|
Early Phase 1 | |
| Completed |
NCT02193698 -
Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial
|
Phase 2 | |
| Completed |
NCT01639898 -
POEMS Syndrome Treatment With Lenalidomide
|
Phase 2 | |
| Recruiting |
NCT00971685 -
The Treatment of Lenalidomide in Patients With POEMS Syndrome
|
Phase 2 | |
| Recruiting |
NCT05476458 -
To Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During POEM Using GF 1500 UGI Scope
|